MDXXF (Pharmala Biotech Holdings) ROCE %: -62.44% (As of Feb. 2026)

What is Pharmala Biotech Holdings ROCE %?

Pharmala Biotech Holdings MDXXF +7.74% 35 ROCE % is -62.44% as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 35/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharmala Biotech Holdings's annualized ROCE % for the quarter that ended in Feb. 2026 was -62.44%.

Pharmala Biotech Holdings (OTCPK:MDXXF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharmala Biotech Holdings ROCE % Related Terms

Pharmala Biotech Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings ROCE % Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Aug25

ROCE %

-94.45

-42.58

-45.23

-38.11

-95.92

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
ROCE %	Get a 7-Day Free Trial															-125.92	-71.90	-59.02	-56.50	-62.44

35GF Score

Pharmala Biotech Holdings Inc MDXXF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pharmala Biotech Holdings ROCE % Calculation

Pharmala Biotech Holdings's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2025 )		(A: Aug. 2024 )		(A: Aug. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2025 )		(A: Aug. 2024 )		(A: Aug. 2025 )
	=	-1.55	/	( ( (2.122 - 0.672)	+	(2.479 - 0.697) )	/ 2 )
	=	-1.55	/	( (1.45	+	1.782)	/ 2 )
	=	-1.55	/	1.616
	=	-95.92 %

Pharmala Biotech Holdings's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2026 )		(Q: Nov. 2025 )		(Q: Feb. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2026 )		(Q: Nov. 2025 )		(Q: Feb. 2026 )
	=	-1.02	/	( ( (2.418 - 0.731)	+	(2.293 - 0.713) )	/ 2 )
	=	-1.02	/	( ( 1.687	+	1.58 )	/ 2 )
	=	-1.02	/	1.6335
	=	-62.44 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -62.44% mean?

Pharmala Biotech Holdings (MDXXF) has a ROCE % of -62.44% as of Feb. 2026.

Is Pharmala Biotech Holdings' ROCE % too high?

Pharmala Biotech Holdings' current ROCE % is -62.44%. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Pharmala Biotech Holdings' ROCE % compare to VRTX and REGN?

Pharmala Biotech Holdings' ROCE % of -62.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Pharmala Biotech Holdings's current ROCE % is -62.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pharmala Biotech Holdings stock overvalued right now?

Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current ROCE % is -62.44%. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current ROCE % is -62.44% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

ROCE %: -62.44%
GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:BLAB XCNQ:DOSE XCNQ:PREV NEOE:BMND TSXV:HEM TSXV:MRVL XCNQ:SKNY TSX:CSCI XCNQ:GLOW XCNQ:BETR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MDMA:Canada

Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website https://www.pharmala.ca

Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.

35GF Score

Get the complete analysis for MDXXF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11

Price

$0.15

GF Value

View MDXXF Analysis

See ROCE % data for all stocks →